Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro

The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

(2015) Rishil J. Kathawala et al.   DRUG RESISTANCE UPDATES

Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems

(2015) Teddy S Nagaria et al.   NEOPLASIA

ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development

(2014) Young Choi et al.   CURRENT PHARMACEUTICAL DESIGN

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance

(2014) Nagaraju Anreddy et al.   MOLECULES

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs

(2014) Nadine Löschmann et al.   Translational Oncology

Cyclin-Dependent Kinase Modulators and Cancer Therapy

(2013) Marialucia Gallorini et al.   BIODRUGS

Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

(2013) L N Eadie et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)

(2013) Jakub Hofman et al.   PLoS One

Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro

(2013) Daniela Cihalova et al.   PLoS One

Cyclin dependent kinases in cancer

(2012) Miriam Canavese et al.   CANCER BIOLOGY & THERAPY

Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine

(2012) Bijun Xia et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261

(2012) Keith C. Bible et al.   GYNECOLOGIC ONCOLOGY

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

(2012) J. E. Karp et al.   HAEMATOLOGICA

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

(2012) Maggie J Rathos et al.   Journal of Translational Medicine

Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters

(2011) S. Shukla et al.   CURRENT DRUG TARGETS

The Challenge of Exploiting ABCG2 in the Clinic

(2011) Robert W. Robey et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

The CDK inhibitors in cancer research and therapy

(2011) Jonas Cicenas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine

(2011) E Walsby et al.   LEUKEMIA

The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy

(2011) Chung-Pu Wu et al.   MOLECULAR PHARMACEUTICS

Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone

(2011) Jakub Hofman et al.   PHARMACOLOGICAL RESEARCH

Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters

(2011) M Saxena et al.   Cell Death & Disease

Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases

(2010) An-Kui Yang et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice

(2009) L. Zhou et al.   DRUG METABOLISM AND DISPOSITION

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Utilization of membrane vesicle preparations to study drug–ABC transporter interactions

(2008) Hristos Glavinas et al.   Expert Opinion on Drug Metabolism & Toxicology

Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges

(2008) Suneet Shukla et al.   Expert Opinion on Drug Metabolism & Toxicology